<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-146724</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">RS3PE syndrome: an update on its treatment using the presentation of a case</dc:title>
<dc:description xml:lang="en">The present study was undertaken in order to try to clarify certain aspects of RS3PE syndrome, for which there is no unanimity of opinion in the current literature. An attempt will be made to clarify the best and most suitable drug for treatment, and the dosage duration. In order to do this, a literature search was performed, and a review is presented of the 108 cases collected. In 95% cases glucocorticoids were the most used, with prednisone in being used in 68.5% of cases. Although there is no unanimity criteria regarding the dosage and duration, 73.8% cases were treated with a prednisone dose from 15 to 20 mg/day (median 18.2 mg/day, SD 8.9). Two-thirds (66.1%) of cases were treated for 3 to 6 months (median 5.3 months, SD 3.8). A case is presented that serves as a common thread of these observations (AU)</dc:description>
<dc:creator>Amodeo, MC</dc:creator>
<dc:creator>Rodríguez, M</dc:creator>
<dc:creator>Poyato, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El objetivo de este estudio es aclarar algunos aspectos relevantes del síndrome RS3PE sobre los que hay discrepancias en la literatura médica actual: los fármacos utilizados para su tratamiento, las dosis más adecuadas y la duración del mismo. Para ello realizamos una revisión bibliográfica recopilando 108 casos. En un 95% de los casos se trataron con glucocorticoides, siendo el más utilizado la prednisona (68,5%). Aunque no hay unanimidad de criterios en cuanto a posología y duración, el 73,8% de los casos que fueron tratados con prednisona recibieron dosis entre 15 y 20 mg/día (dosis media de 18,2 mg/día, DE 8,9). Un 66,1% de los casos fueron tratados entre 3 y 6 meses (promedio 5,3 meses, DE 3,8). Presentamos un caso que sirve como hilo conductor de estas observaciones (AU)</dc:description>
<dc:source>SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.);41(8): 429-434, nov.-dic. 2015. tab</dc:source>
<dc:identifier>ibc-146724</dc:identifier>
<dc:title xml:lang="es">El síndrome RS3PE: actualización de su tratamiento a propósito de un caso</dc:title>
<dc:subject>^d11756^s22083</dc:subject>
<dc:subject>^d1178^s22016</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d32355^s22073</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d28302^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201512</dc:date>
</metadata>
</record>
</ibecs-document>
